J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma

In a major win for Johnson & Johnson and Legend Biotech, their star CAR-T therapy Carvykti showed it can prolong the lives of patients with previously treated multiple myeloma.

J&J and Legend announced the “statistically significant and clinically meaningful” overall survival win Tuesday from the phase 3 CARTITUDE-4 trial, which compared Carvykti with standard combination therapies in myeloma patients who had tried one to three prior lines of therapy.